ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
1. Introduction
This is the second European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] and anaemia.1 Up to 50% of patients with IBD will develop at least one EIM, which may impact each body system2; hence they are a source of considerable morbidity, or even mortality in the case of primary sclerosing cholangitis [PSC] or venous thromboembolic events [VTE]. Broadly, EIMs can be categorized as classical, arising from inflammatory pathology at distant sites, the consequences of systemic inflammation and treatment, or wider associations3 [summarized in Figure 1]. The underlying pathophysiology of extraintestinal inflammation is not fully understood. Potential driving forces include extension of the immune-mediated response from the inflamed gut to other organs, with shifts in leukocyte trafficking,4 changes to the intestinal microbiota,5 and underlying predisposing genetic factors.6 The systemic consequences of IBD lead to broader associations, including VTEs and anaemia. Whether these are strictly EIMs is of debate,3 but they are included within this guideline as they incur a considerable health burden to patients with IBD.
![Extraintestinal manifestations in IBD [adapted from Hedin et al 2019, figure created with BioRender®]. Extraintestinal manifestations (EIMs) may occur in every system of the body and can broadly be classified as Classical: inflammatory process occurring at distant sites, Associations: associations with other immune-mediated disorders, and Complications: complications of systemic inflammation, Treatment: side effects of IBD therapy. PSC—primary sclerosis cholangitis, AIH—autoimmune hepatitis, MS—multiple sclerosis, CVA—cerebrovascular accident, ILD—interstitial lung disease, VTE—thromboembolic event.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ecco-jcc/18/1/10.1093_ecco-jcc_jjad108/1/jjad108_fig1.jpeg?Expires=1712588418&Signature=MmR82FqEZCB39IwLaBlNFE3BQJRKt1eC2BwjIhpbh1oqggwVLQZAct1dTgC7x4gvGRdKWnM7~jJBWhNFmq8msOtQh~iFcuLckPeBlDSFBAOcTSVI5QxCyBnMD4f8lhNxBv3rPm6S7fwD~3WbD91QFopfGRnBEHuUjaL-V9PHVvb0OufaSc8A-~XQCtZ1nlRjEzLCIQz5W2kl~BwPOcF~kgoT-UN7CCu3PAgeCIXl56y7gFFMpZK7LZIJEQROD~qTDa1JA4tpI-Phooy7quwQfxicm8VEP4uEcirREwn-7xdRqF-EmTeuwS7hCxfnl0ssnx7sFHVsmzttQlmojsqy4w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Extraintestinal manifestations in IBD [adapted from Hedin et al 2019, figure created with BioRender®]. Extraintestinal manifestations (EIMs) may occur in every system of the body and can broadly be classified as Classical: inflammatory process occurring at distant sites, Associations: associations with other immune-mediated disorders, and Complications: complications of systemic inflammation, Treatment: side effects of IBD therapy. PSC—primary sclerosis cholangitis, AIH—autoimmune hepatitis, MS—multiple sclerosis, CVA—cerebrovascular accident, ILD—interstitial lung disease, VTE—thromboembolic event.
This guideline was created according to ECCO’s standardized methodology. A panel of 20 gastroenterologists was selected by the ECCO Guidelines Committee from a competitive pool of applicants. Two guidelines committee members, HG and TK, were selected as project coordinators. Participating experts were split into four working groups [WGs], and a leader was selected for each. Topics were determined by the project coordinators and WG leaders and split between the four groups. ECCO recognizes the need for a multidisciplinary approach when managing EIMs in IBD. As such, we included the following invited experts from other disciplines from project onset: CB [dermatology], UM-L [rheumatology], SZ [vascular medicine], CS [hepatology], and TH [ophthalmology].
For each topic, a clinically relevant question was formulated and used to define a Population, Intervention, and Comparator[s] of interest. These informed a systematic literature search, performed by a professional librarian using PubMed/Medline, Embase, and the Cochrane Central databases. Abstracts from each literature search were screened by two participants. Full texts of potentially relevant abstracts were retrieved and evaluated in full by both authors, who reached agreement on which papers were most relevant to inform the answer to the clinical question.
A consensus statement and supporting text were drafted for each topic and posted on an online guidelines platform. Two rounds of online voting and revisions took place. During the second voting round, ECCO national representatives also participated, although consensus was calculated from votes cast by members of this project alone. The participants met in October 2022 to discuss and vote on statements and recommendations. Consensus was defined as agreement by 80% or more of participants. Resulting consensus statements [with percentage agreement] are presented in this paper. We would like to stress the importance of interpreting each statement within the context of the supporting text provided, which is designed to add context and is of particular relevance given the paucity of data available for some of these critically important topics. The level of evidence supporting all statements is defined using the Oxford methodology.7

